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Abstract
Background: Evidence-based screening guidelines are needed for women under 40 with a family history of breast
cancer, a BRCA1 or BRCA2 mutation, or other risk factors. An accurate assessment of breast cancer risk is required to
balance the benefits and risks of surveillance, yet published studies have used narrow risk assessment schemata for
enrollment. Breast density limits the sensitivity of film-screen mammography but is not thought to pose a limitation to
MRI, however the utility of MRI surveillance has not been specifically examined before in women with dense breasts.
Also, all MRI surveillance studies yet reported have used high strength magnets that may not be practical for dedicated
imaging in many breast centers. Medium strength 0.5 Tesla MRI may provide an alternative economic option for
surveillance.
Methods: We conducted a prospective, nonrandomized pilot study of 30 women age 25–49 years with dense breasts
evaluating the addition of 0.5 Tesla MRI to conventional screening. All participants had a high quantitative breast cancer
risk, defined as ≥ 3.5% over the next 5 years per the Gail or BRCAPRO models, and/or a known BRCA1 or BRCA2
germline mutation.
Results: The average age at enrollment was 41.4 years and the average 5-year risk was 4.8%. Twenty-two subjects had
BIRADS category 1 or 2 breast MRIs (negative or probably benign), whereas no category 4 or 5 MRIs (possibly or
probably malignant) were observed. Eight subjects had BIRADS 3 results, identifying lesions that were "probably benign",
yet prompting further evaluation. One of these subjects was diagnosed with a stage T1aN0M0 invasive ductal carcinoma,
and later determined to be a BRCA1 mutation carrier.
Conclusion: Using medium-strength MRI we were able to detect 1 early breast tumor that was mammographically
undetectable among 30 young high-risk women with dense breasts. These results support the concept that breast MRI
can enhance surveillance for young high-risk women with dense breasts, and further suggest that a medium-strength
instrument is sufficient for this application. For the first time, we demonstrate the use of quantitative breast cancer risk
assessment via a combination of the Gail and BRCAPRO models for enrollment in a screening trial.
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Background
The sensitivity of mammography has been observed to be
lower in women <50 years of age (63–86%), compared
with women ≥50 years (89–94%) [1-3]. The U.S. Preven-
tive Services Task Force meta-analysis found that the time
required to obtain a risk reduction in breast cancer mor-
tality rates is longer for younger women [4]. The lower
sensitivity of mammography in young women has been
ascribed to their higher prevalence of mammographically
dense breasts and, perhaps, faster tumor growth rates
[1,2].
About 25% of all women have dense breast tissue, and
this physiology is more common in younger women [5-
9]. Indeed, dense breast tissue has been found to be an
independent risk factor for breast cancer [10,11]. Screen-
ing mammography may have limited utility in women
with dense breast tissue for a variety of reasons, including:
similar attenuation properties of breast lesions with dense
glandular tissue; more radiation scatter and therefore
higher required dose; and difficulty obtaining adequate
exposure without image degradation [12]. Among women
in a screening study, the sensitivity of mammography var-
ied from 80% in women with extremely fatty breasts to a
mere 30% for those with extremely dense breasts, and the
odds ratio of an interval tumor was 9.47 for the latter
group [13].
Younger women have a lower prevalence of breast cancer,
which must be balanced against the false-positive rate of
screening mammography [4]. However, the risk of breast
cancer in young women with specific risk factors may
equal or exceed that of older women for whom screening
is unequivocally recommended. About 6% of breast can-
cer cases in women < 50 years of age are due to germline
mutations in the BRCA1 or BRCA2 breast and ovarian
cancer susceptibility genes [14,15]. Carriers are at excep-
tionally high risk, with potential breast cancer onset as
early as the third decade and cumulative risk to age 40
reaching up to 20% [16]. While prophylactic mastectomy
is the most effective risk-reducing therapy, many carriers
would opt for heightened surveillance instead, given a suf-
ficient degree of confidence in the opportunity for early
detection [17].
There is evidence that breast density in BRCA1 mutation
carriers is similar to that of women in the general popula-
tion [18]. Thus, resultant technical limitations of screen-
ing mammography are likely to apply to this group of
relatively young high-risk women [19]. Specifically, in a
study comparing mammography among 34 BRCA1  or
BRCA2 mutation carriers with breast cancer vs. disease-
free controls, false-negative mammography correlated
independently with BRCA1/2 mutation, the histological
feature of prominent pushing margins, and high breast
density [20].
Also relevant to the management of germline mutation
carriers is the involvement of the BRCA1 and BRCA2 pro-
teins in recombination repair of ionizing radiation-
induced double-strand DNA breaks [21-23]. Possible car-
cinogenic consequences of low-dose irradiation for young
mutation carriers undergoing earlier mammography
screening must be considered [21].
An adjunct to screening mammography is particularly
needed for young women at high risk of breast cancer
whose imaging is limited by radiographically dense
breasts. Contrast-enhanced magnetic resonance imaging
(MRI) of the breast is a potential surveillance approach
that is highly sensitive, is not limited by radiographic den-
sity, and poses no radiation risks. The sensitivity of con-
trast-enhanced breast MRI for breast cancer detection has
been reported to be as high as 94%–100% [24-26]. Specif-
icities are more variable, with values ranging from 37%–
97% [25-28]. Recent larger prospective screening studies
conducted in high-risk cohorts confirm high sensitivities
and demonstrate, for the first time, high specificities, as
well [29,30].
Methods
Study design
This study is a prospective, nonrandomized clinical trial
designed to investigate the usefulness of a prototypical
midfield strength Magnetic Resonance Imaging System in
a screening setting using quantitative risk assessment for
eligibility. The study looked at the addition of 0.5 Tesla
MRI to a screening regimen for young women at high risk
of breast cancer with dense breast tissue consisting of con-
ventional screening modalities. The study was designed as
a pilot study, with an enrollment over one year of thirty
women. The data presented are a summary of this pilot
study.
Patient selection and consent
Thirty women between the ages of 25 and 49, inclusively,
without a personal history of invasive or non-invasive
breast cancer were recruited for this study between 10/27/
99 and 4/19/00 via the joint Comprehensive Breast and
Cancer Genetics Programs of the University of Pittsburgh
Cancer Institute and Magee-Womens Hospital of UPMC.
Women were required to have a negative or benign mam-
mographic and physical evaluation within three months
of enrollment. All subjects had mammographically dense
breast tissue described as "heterogeneously" or "extremely
dense" according to the American College of Radiology
Breast Imaging Reporting and Data System (BIRADS) lex-
icon [31]. Categorization of increased breast density was
first determined by report on prior conventional film-BMC Women's Health 2006, 6:10 http://www.biomedcentral.com/1472-6874/6/10
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screen mammographic examination, performed within 3
months of enrollment. Mammogram films were obtained
and reviewed by the lead radiologist (JHS) to verify the
presence of increased breast density. The four standard
American College of Radiology BIRADS breast composi-
tion patterns are: (1) almost entirely fat; (2) predomi-
nantly fat with scattered fibroglandular densities; (3)
heterogeneously dense; and (4) extremely dense. Women
with fatty breasts or scattered areas of density with no
focal areas of concentration were not eligible for the
study. Exclusion criteria included a contraindication to
MRI, breast implants, mastectomy, or a history of allergic
reaction to gadolinium. Quantitative risk analysis was
performed on all women prior to enrollment using the
Gail and BRCAPRO-based CancerGene models. Partici-
pants had a minimum 5-year breast cancer risk on either
model of 3.5% and/or a known mutation in BRCA1 or
BRCA2.
This study was reviewed and approved by the Magee-
Womens Hospital of UPMC Institutional Review Board
(MWH-99–081). The study was explained to all partici-
pants and informed consent was obtained. Genetic testing
was performed following genetic counselling under pro-
tocol MWH-97-082.
Risk analysis
Absolute 5-year breast cancer risk was determined using
the Gail and BRCAPRO models [32,33], both of which
have been extensively validated [34,35]. The National
Cancer Institute Gail model computer program directly
calculates absolute 5-year risk of invasive breast cancer
using by using a baseline proportional hazards estimation
and incorporating the following risk factors: age, race,
number of first-degree relatives with breast cancer (maxi-
mum of 2), age at menarche, age at first live birth (or nul-
liparity), number of breast biopsies (with relative risk
adjusted by age), and atypical hyperplasia. The BRCAPRO
program is based on the Berry model [33] and utilizes
Mendelian principles with Bayesian updating to calculate
carrier probabilities for germline BRCA1  and  BRCA2
mutations by capturing extensive family history informa-
tion about female and male breast cancer, ovarian cancer,
age at cancer diagnosis, current age or age of death for rel-
atives with and without cancer, and ethnicity. Absolute 5-
year risk of breast cancer was then determined as follows:
(the probability of being a BRCA1/2  mutation carrier
based on BRCAPRO) × (the yearly incidence of breast can-
cer in a mutation carrier, specific to the decade of life [36])
× (5 years). These calculations were performed automati-
cally using the CancerGene program [37], freely available
on the worldwide web [38].
Family history and personal risk factors were obtained
through personal interview to obtain the most complete
and accurate history possible. This information was col-
lected on case report forms and entered into the models
on computer. If both models resulted in a 5 year risk of
≥3.5%, the higher value was used. As per the CancerGene
program, known BRCA1  and BRCA2  carriers reach the
3.5% 5 year risk threshold at ages 27 and 32 years, respec-
tively.
All women had a negative or benign breast examination,
including physical examination and mammography
within 3 months prior to study enrollment. All enrolled
participants received a screening MRI as described below.
Device information
This study utilized a contrast-enhanced magnetic reso-
nance imaging system produced by Aurora Imaging Tech-
nology, Wilmington, MA. The system involves a 0.5 Tesla
magnet with gadolinium as a contrast agent. The Aurora
system is a dedicated system specifically designed for
breast imaging.
The 0.5T MRI uses local volume transmit/receive coils and
a gradient strength of 1 G/cm. The RF system consists of a
wide band receiver operating at 21 MHz. There is 0.3
kwatts RF power. Images can be viewed at either a work-
station or by film generated from an interface with a laser
camera.
Magnetic resonance imaging
Patients were scanned in the prone position and placed
into the magnet feet first. Images were acquired in the
axial plane with both breasts imaged simultaneously. The
field of view was variable from 8–46 cm transverse and 20
cm axial. Standard 2D and 3D gradient echo and spin
echo sequences were used. The dynamic, contrast-
enhanced series was 3D. The matrix was 256 × 256 × 64
(x, y, z). The first sequence was non-contrast: T1 –
Weighted GE, TR = 14 ms and TE = 6.0 ms, giving 64 2.0
mm thick slices, with an in-plane resolution of 1.4 mm ×
1.4 mm. After completion of the non-contrast scan, intra-
venous gadolinium was administered at a dose of 0.1
mmol/kg of body weight at approximately 1.0 cc/sec.
Post-contrast axial imaging was performed immediately,
followed by a second scan approximately 4 minutes later
for delayed imaging. Total imaging time is approximately
4 minutes per sequence or 12 minutes for actual imaging
(this relatively long time was not inconsistent with proto-
cols during the time of the study). Immediate and delayed
subtraction views were generated by computerized sub-
traction of the pre-contrast image from both the immedi-
ate and delayed post-contrast images. This post-imaging
subtraction was used as the method of fat suppression,
i.e., no active fat suppression was used. Regions of interest
(ROIs) were placed on enhancing lesions of concern andBMC Women's Health 2006, 6:10 http://www.biomedcentral.com/1472-6874/6/10
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three point time dependent intensity curves were gener-
ated for each region.
Lesions were characterized using both morphologic and
kinetic criteria similar to the manner described [39,40].
An MR BIRADS category was assigned ranging from 1
(negative), 2 (benign), 3 (probably benign) 4 (possibly
malignant), to 5 (probably malignant). Morphology was
described according to the lexicon developed by the MRI
working group, which was available to us prior to the final
publication date [41]. Criteria used to evaluate and rate
MRI-detected lesions were those published by Schnall et
al. [42] combined with kinetic information. Kinetics were
described by visually comparing the immediate post con-
trast images to the delayed post contrast images. Lesions
were scored as early enhancement and early washout,
early enhancement and delayed washout, or delayed
enhancement. In a manner similar to Hylton et al. [43],
lesions were considered suspicious if they had either mor-
phologic or kinetic features suspicious for malignancy
(rapid wash-in and washout). In addition, lesions graded
as BIRADS 3 by either morphologic or kinetic criteria were
offered further evaluation using ultrasound. Ultrasound
results confirmed the MRI findings, but otherwise added
no new information.
Results
Thirty women were enrolled in the study. The average age
at enrollment was 41.1 years. The average 5-year breast
cancer risk at enrollment, using either the Gail model or a
BRCAPRO-based cancer risk model, was 4.8%. The Gail
model was actually only used to establish eligibility in 7
cases, whereas the BRCAPRO-based model was used in
majority of cases, 23.
MRI results classified according to BIRADS category are
shown in Figure 1 No results were observed in BIRADS
categories 4 or 5. Subjects with MRI results of BIRADS 1 or
2 received no additional breast evaluations. Subjects with
BIRADS 3 results were evaluated as summarized in Table
1. Follow-up involved invasive procedures in 4 of these 8
subjects. Among the 8 patients with BIRADS 3 results,
one, subject 006, was diagnosed with stage I invasive duc-
tal carcinoma.
Imaging results for subject 006 are given in Figure 2 (for a
full clinical description of this patient, as well as live-cell
analysis of her breast tissue for indices of proliferation,
differentiation and genomic instability, see [44]). Her
mammogram is depicted in Figure 2A, showing heteroge-
neously dense breast tissue. The MR images for this
patient are shown in Figures 2B and 2C. In the upper-
outer left breast there was a small (approximately 1 cm),
round, well-demarcated enhancing lesion, seen on both
the initial delay after contrast injection and the delayed
contrast enhanced subtraction images. This lesion
appeared to accumulate contrast to a greater extent on the
delayed subtraction images with an additional lesion
adjacent to the first. In the right breast just above the nip-
ple level medial and close to the chest wall an additional
lesion was seen in the pre-contrast image. This lesion was
approximately 1.5 cm, smooth and round. Core biopsy of
the left breast revealed infiltrating ductal carcinoma in 2
of 5 core fragments; high nuclear grade, with no lym-
phatic invasion seen. The core biopsy of the right breast
demonstrated benign pathology, specifically, fibrosis with
focal ductal epithelial hyperplasia. The patient chose to
undergo left modified radical mastectomy with left axil-
lary lymph node dissection and contralateral prophylactic
total mastectomy because of her genetic risk status. Final
pathology in the left breast was consistent with the imag-
ing and core biopsy in size and description. Tumor size
was 8 mm in greatest dimension, nuclear grade III, ER/PR
and Her2/neu negative, and the nodal status (0/4) was
negative (stage T1aN0M0). This subject represented 3.3%
of the sampled high risk population and 12.5% of the
population with "probably benign" MRIs.
Interim follow-up was required for 8 of 30 (27%) sub-
jects, but only 4 (13%) underwent an invasive procedure.
Clinical follow up was available on all 29 disease-free sub-
jects at least one year beyond the performance of the study
Figure 1
Table 1: Post-MRI evaluation procedures for the BIRADS 
category 3 results
Procedure Type Invasive Non-Invasive
Short-Term (6 month) Clinical Follow-Up 1
Ultrasound with Normal Results 3
Ultrasound with Cyst Aspiration 1
Ultrasound with Fine Needle Aspiration 1
Ultrasound with Core Biopsy 2
Total Patients: 44BMC Women's Health 2006, 6:10 http://www.biomedcentral.com/1472-6874/6/10
Page 5 of 10
(page number not for citation purposes)
Imaging of subject 006 Figure 2
Imaging of subject 006. A) Subject 006 pre-MRI mammogram demonstrating heterogeneously dense breast tissue. There is 
no evidence of a cancerous lesion. B) Pre-contrast MR image showing an approximately 1.5 cm, smooth, round lesion in the 
right breast just above the nipple level medial and close to the chest wall (arrowhead). Core biopsy of this lesion demonstrated 
benign pathology, specifically, fibrosis with focal ductal epithelial hyperplasia [44]. C) Post-contrast MR images showing a small 
(approximately 1 cm), round, well-delineated enhancing mass (arrow) in the left breast at the 1:00 position. This mass was seen 
on both the initial delay after contrast injection (left) and the delayed contrast enhanced subtraction images (right). Core 
biopsy of this lesion indicated infiltrating ductal carcinoma, which was confirmed after removal via modified radical mastectomy 
[44].
C
A
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MRI, which is the standard length of follow up to exclude
occult cancer, and no subjects developed breast carci-
noma. Thus, the patients in BIRADS categories 2 and 3
likely did not harbor occult disease.
Discussion
Without data on cancer-specific mortality reduction, the
decision to employ breast MRI surveillance rests heavily
on other parameters, including test performance charac-
teristics, cost, and methods of maximizing benefit vs. risk.
Recent prospective studies have provided firmer data indi-
cating that high sensitivity can be achieved with breast
MRI without greatly sacrificing specificity. While reduc-
tion in cancer-specific mortality is the gold standard for
surveillance tools, there is a pressing need to supplement
mammography in high-risk women, particularly for
BRCA1 and BRCA2 mutation carriers who are diagnosed
with a high rate of interval tumors, roughly 50% [45].
Breast MRI results in a lower rate of interval tumors while
circumventing the limitations of surveillance for women
with dense breasts. However, for whom should breast
MRI surveillance be employed and what are acceptable
costs?
Medium vs. high field strength MRI
Despite the promise of breast MRI, there are still some
issues that must be resolved prior to its use as a standard
adjunct method of breast cancer surveillance. There is not
yet a standard method in place for such imaging, and no
consensus on how to best interpret lesions detected by
MRI, and whether or when to biopsy lesions detected by
MRI alone [see ref. 31]. Additionally, the high cost of
breast MRI is severely limiting. Not only is there a large
cost associated with the purchase of a high field strength
magnet, but also there are additional costs for housing
and maintaining the unit. The use of medium field
strength magnets has been criticized for their low signal-
to-noise ratio (SNR) per sampling time. However, the use
of a medium field strength magnet, such as a 0.5 Tesla,
would come at significant cost savings of up to 1/3 that of
a higher field strength MRI system. Our study provides
preliminary evidence that a medium field strength breast
MRI system can be effectively used for high-risk surveil-
lance.
There is evidence that the use of a medium field strength
breast MRI system is comparable to a 1.5 T system. In a
study published by Kuhl et al. [46], MRI was performed on
a midfield system without loss of sensitivity as compared
to a high field system. The study looked at 42 patients
imaged on both a 0.5 T and 1.5 T MRI, finding that the
image quality was comparable, and, with certain compen-
sations, the 0.5 T system was more sensitive than the
larger 1.5 T MRI. In a second study, Kuhl et al. [47] imaged
40 patients with nodular lesions using both 0.5 T and 1.5
T field strength units to determine if the two systems were
comparable in selecting benign vs. malignant lesions.
Malignant lesions and fibroadenomas demonstrated a
similar enhancement uptake pattern on both systems. A
rapid wash-out of contrast was seen only in malignant
lesions, which appeared 10 times more frequently using
the 0.5 T system as compared with 1.5 T MRI.
The appearance of T1-weighted gradient echo images gen-
erated from a contrast study depends on the SNR, the con-
trast-to-noise ratio (CNR) and the contrast agent used.
The SNR is a function of the magnetic field strength, mag-
net shim, flip angle, voxel size, receiver gain, RF coil and
image processing parameters. Magnetic field strength
directly affects the SNR and the spin relaxation properties
of the tissue. The SNR is linear with field strength--every-
thing else being equal, 1.5 T magnets produce images with
three times the SNR of images from 0.5 T magnets. In
addition, the T1 of a given tissue/sample type is larger at
higher field strengths. This implies that at a higher field
strength, the spin relaxation of a given tissue/sample may
be changed more that the same tissue/sample at a lower
strength and thus may increase the difference observed in
pre- and post-contrast images.
The CNR is a measure of the average intensity of an object
compared to the average intensity of the noise floor for a
given object and pulse sequence. The CNR is a function of
the relation of the pulse sequence timing parameters (e.g.,
TE, TR) to the spin relaxation properties (e.g., T1, T2) of
the object. Because the contrast agent changes the spin
relaxation properties, it changes the CNR of the image.
Above a minimum SNR threshold, the ability to detect a
lesion using MRI is a function of the change in CNR of
pre- and post-contrast images and the voxel size acquired.
If the configuration of a 1.5T MRI scanner and a 0.5T MRI
scanner is such that both are above the minimum level of
SNR, have comparable CNR changes after adding a con-
trast agent, and have identical voxel sizes and scan dura-
tions, the ability to detect lesions is similar.
Our study demonstrates that medium field strength MRI
can detect tumors that have been missed by conventional
screening mammography. There are, however, certainly
limitations to this initial study, including its small size; up
to 3 months time differential between screening mammo-
gram and MRI; and lack of longitudinal follow up. No
conclusions can be drawn regarding the overall sensitivity
or specificity of screening with the 0.5 T MRI.
Screening guidelines for young high-risk women
There has been a dearth of evidence-based screening
guidelines for women age < 40 with a family history of
breast cancer, a BRCA1 or BRCA2 mutation, or other risk
factors, largely because of the lack of randomized, control-BMC Women's Health 2006, 6:10 http://www.biomedcentral.com/1472-6874/6/10
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led trials to inform the development of such guidelines
[48-50].
As evidence accumulates regarding the efficacy of bilateral
prophylactic mastectomy, data regarding the efficacy of
screening is of paramount importance so that women can
make informed choices. In a large screening study of 251
mutation carriers, a high rate of interval tumors found on
breast self-examination led to the suggestion that more
frequent (i.e. semi-annual) mammography should be
considered, particularly in younger women [51]. How-
ever, among women age 40–69, the estimated cumulative
risk of a false positive result after 10 mammograms is 49%
[52], resulting in additional visits, diagnostic tests, inva-
sive procedures, morbidity, cost, and anxiety. Further-
more, there is evidence that false-positive rates are higher
in younger women [53-55]. Ultimately, the sequelae of
screening (such as biopsies) can spur the decision to
undergo prophylactic surgery, giving one pause about rec-
ommending more frequent screening.
The variations in sensitivity and specificity for breast MRI
exist for several reasons, including technical factors [56],
interpretation criteria [28,30,38], patient selection, con-
comitant use of conventional imaging, and the level of
pathologic verification of the abnormalities detected. The
large disparity in specificities results from a variety of tech-
nical factors. For instance, the lowest reported specificity
was calculated without the use of morphologic features or
quantification of enhancement, and certain high-risk
lesions, such as atypical ductal hyperplasia, were consid-
ered as false positives [24].
All high-risk MRI screening studies reported thus far have
used high field-strength magnets. Stoutjesdijk et al. [57]
found that for the indeterminate BIRADS score of 3, the
sensitivity of breast MRI was 100% with a specificity of
93% (95% confidence interval = 90%–96%) and a posi-
tive predictive value of 43%. Warner et al. [58] reported a
sensitivity of 100% and noted that all four false negative
mammograms had a BIRADS score of 1. In this study,
increased breast density appeared to contribute to the
poor sensitivity of mammography. An update of this
study reporting findings on 236 Canadian women aged
25 to 65 years with BRCA1 or BRCA2 mutations found a
specificity of 95.4% based on biopsy of BIRADS level 4
and 5 lesions, but did not take into account the effect of
breast density, nor the non-biopsy interventions engen-
dered by level 3 lesions [30]. High-risk women may be
particularly susceptible to the emotional turmoil triggered
by a diagnostic workup for breast cancer, considering their
high-risk family histories.
The largest breast MRI surveillance study reported to date,
based on 1909 eligible women including 358 germ-line
mutation carriers, found a specificity of 89.8% for workup
of level 3, 4, and 5 lesions [29]. However, this study did
not examine possible differences in test performance
among women at varying levels of risk, nor was breast
density taken into account. While a lower limit of 15%
lifetime risk constituted study eligibility, it remains
unclear whether this risk level merits high-risk surveil-
lance, particularly in women with average mammo-
graphic breast density. Our ongoing studies of
surveillance screening with medium field strength MRI
have shown that the false-positive rate is three-fold lower
than that of mammography [59].
Conclusion
Toward quantitative balancing of risks and benefits in 
surveillance
We contend that the benefits of breast cancer surveillance
cannot be satisfactorily balanced against the risks of
screening without an accurate assessment of absolute
breast cancer risk. We report for the first time the use of
quantitative breast cancer risk assessment for use in
enrollment in a breast cancer screening pilot study by
combining both the established Gail model and a purely
genetic model which estimates BRCA1/2 mutation risk via
BRCAPRO. Kriege et al. [29] used the Claus model [60] for
risk stratification, but this model has not been as exten-
sively validated as either the Gail or BRCAPRO models. In
particular, omission of family history of ovarian cancer in
the Gail and Claus models is one factor that can lead to
underprediction of breast cancer risk; this constitutes a
serious limitation to using either model alone [61]. The
Gail model identifies at least three types breast cancer risk
factors: genetic risk associated with family history, risk
based on lifestyle factors associated with hormonal
effects, and risk associated with suspicious breast pathol-
ogies, regardless of the basis of this risk. Genetic analysis
of the subjects who developed breast cancer in the NSABP
P-1 Breast Cancer Prevention Trial indicates that the Gail
model inefficiently identifies BRCA1 and BRCA2 muta-
tion carriers, since only 6.6% (19/288) of that high-risk
population carried such mutations [62].
Supplementation of the Gail model with the BRCAPRO
model allows for a much more efficient ascertainment of
women at high risk for breast cancer specifically due to the
possibility that they carry a mutant BRCA1  or  BRCA2
gene, based on our accumulated knowledge of hereditary
breast-ovarian cancer syndrome. Since 23 of our 30 sub-
jects were enrolled based on their BRCAPRO risk rather
than their risk based on the Gail model, this group repre-
sents a rather unique "high-risk" population, with per-
haps more in common with studies in BRCA1/2 carriers
such as that of Warner et al. [30] than previous popula-
tions enrolled through the exclusive use of the Claus
model. We are the first to incorporate a quantitative can-BMC Women's Health 2006, 6:10 http://www.biomedcentral.com/1472-6874/6/10
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cer risk component based on genetic risk as assessed by
BRCAPRO, without direct confirmation by gene testing.
This is important because some subjects with BRCA1 or
BRCA2 mutations may be reluctant to enroll in a trial
restricted to mutation carriers, since their genetic status
would be known by virtue of their participation. Enroll-
ment according to quantitative risk can allow women who
are not yet prepared for genetic testing to participate in a
high-risk surveillance trial.
We have advanced the rationale for quantitative risk
assessment in chemoprevention trials, with the advan-
tages of improved power using a smaller study popula-
tion, shorter study duration and lower cost [63]. The same
rationale applies to surveillance trials. In addition, sub-
jects at higher risk of breast cancer have a greater ratio of
benefit vs. risk than average-risk women since, if the sur-
veillance modality is efficacious, they have a greater
opportunity for early detection. For trials that seek to
measure specificity, breast cancer events are not crucial to
determining the required sample size, yet for ethical rea-
sons, subjects who stand to benefit the most ought to be
preferentially studied. Ours is the first study to concen-
trate on high-risk women with mammographically dense
breast tissue; the poorer sensitivity of mammography in
this group should contribute to an especially high ratio of
benefit vs. risk.
The concomitant use of the Gail and BRCAPRO-based
models allows for the identification of a broad array of
high-risk women [64]. The report of the Working Groups
on Breast MRI advises that "a careful analysis of the
woman's actual risk for breast cancer" be done when con-
sidering the appropriateness of screening MRI [65]. They
urge the development of partnerships with high-risk clin-
ics and/or clinicians with significant experience with high-
risk women. Ultimately, since the conduct of randomized,
controlled trials in high-risk women faces numerous chal-
lenges, medical decision making models may be useful for
balancing the benefits and risks using such parameters as
age, quantitative breast cancer risk, and breast density.
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